Business
Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a
About this update from Waldencast Plc
[{"type":"text","content":"Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare\nNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced the launch of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program. This structured clinical collaboration initiative accelerates aesthetic innovation through practice-led insights and will support the introduction of Obagi® saypha® MagIQ™ – the company's first FDA-approved injectable hyaluronic acid (HA) filler with category-leading features including high useable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile1. “ALOHA reflects our commitment to launching innovation differently and supporting category growth,” said Drew Fine, U.S. General Manager, Professional Channel. “By gathering real-world data across diverse practice settings, we will demonstrate how Obagi® saypha® MagIQ™ and Obagi skincare can drive practice success and patient satisfaction. The program's inclusive design embodies our Aesthetics for All™ ethos and invites broad industry participation.” The ALOHA program creates a platform for practices to integrate real-world clinical experience into the product lifecycle. Participants will incorporate Obagi® saypha® MagIQ™ into routine treatments and provide structured feedback via standardized surveys from injectors and practice owners. This authentic, practice-driven approach captures insights beyond pivotal trials, informing post-launch education, scientific content, and wider adoption. The program is expected to become the largest real-world evaluation of a newly launched HA injectable. “We are thrilled to partner with our valued Obagi providers to introduce this MagIQ-al new injectable,” added Mr. Fine. “Practices interested in participating are encouraged to sign up or contact their Obagi representative for more details.” For more information about ALOHA, visit https://obagi-professional.com About Obagi MedicalObagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with ...